United Kingdom

People: Bellerophon Therapeutics Inc (BLPH.OQ)

BLPH.OQ on NASDAQ Stock Exchange Global Market

16 Aug 2019
Change (% chg)

$0.01 (+0.99%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Amin, Naseem 

Dr. Naseem Amin, M.D. is an Independent Director of the Company effective June 29, 2015. Dr. Amin, who was also appointed to the Audit Committee, has broad industry experience in the Biotech and Medical Device industry. Until 2014, he was Chief Scientific Officer of Smith and Nephew Plc, where he provided scientific leadership to the organization. From 2005 to 2009, Dr. Amin was Senior Vice President, Business Development at Biogen Idec and from 1999 to 2005, was with Genzyme Corporation, most recently as Head, International Business Development. At both Biogen and Genzyme, Dr. Amin successfully initiated and executed a number of transformative acquisitions and transactions. He has also led the clinical development of five currently marketed therapeutic products. Dr. Amin began his career at Baxter Healthcare Corporation, where he served as Director, Medical Marketing and Portfolio Strategy, Renal Division. Dr. Amin earned his medical degree from the Royal Free School of Medicine, London, and an MBA from the Kellogg Graduate School of Management, Northwestern University. He is a Venture Partner at Advent Life Sciences, serves as an Advisory Board member for Imperial College, Department of Biomedical Engineering, and serves as Chairman of OPEN-London, a non-profit organization focused on encouraging and mentoring South Asians from Pakistan who are interested in starting entrepreneurial companies.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --